EUVIMEDEUVIMED entdecken
Vergleichsstudie

Years of life lost and mortality rates from metastatic prostate cancer in contemporary African Americans vs. Caucasians

Leonardo Quarta iD, Michele Nicolazzini, Calogero Catanzaro, Federico Polverino, Michele Petix, Maximilian Filzmayer, Nick J Lee, Jordan A Goyal, Alessandro Volpe, Riccardo Schiavina, Nicola Longo, Luca Carmignani und 9 weitere

World Journal of Urology · 23.02.2026 · 44 (1)

DOI: 10.1007/s00345-026-06295-3 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift World Journal of Urology, online erschienen am 23.02.2026. Verfasst von Leonardo Quarta und 20 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada. quarta.leonardo@hsr…. Hauptthemen laut MEDLINE: Black or African American, Life Expectancy, Prostatic Neoplasms, White. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: It is unknown whether the historical survival disadvantage of African American metastatic prostate cancer (mPCa) patients persists in abiraterone and androgen receptor pathway inhibitors (ARPIs) eras. METHODS: In Surveillance, Epidemiology, and End Results (SEER) database (2017–2021), African American and Caucasian mPCa patients aged 40–80 years treated across abiraterone (2017–2018) and ARPI (2019–2021) eras were identified. Age- and sex-matched controls were generated (Social Security Administration life tables and Monte Carlo simulation). Years of life lost (YLL) were quantified for mPCa patients and controls. Subsequently, propensity score matching (PSM) and multivariable competing-risks regression (CRR) models were used. RESULTS: In abiraterone era, YLL were 8.1 in African Americans vs. 5.4 in Caucasians (Δ: 2.7). In ARPI era, YLL were 4.6 in African Americans vs. 2.6 in Caucasians (Δ: 2.0). The 24-months cancer-specific mortality (CSM) was 30.3% in African Americans vs. 25.4% in Caucasians (multivariable hazard ratio [mHR]: 1.21, p < 0.001) in abiraterone era and 23.3% in African Americans vs. 25.0% in Caucasians (mHR: 1.01, p = 0.8) in ARPI era. The 24-months other-cause mortality (OCM) was 6.6% in African Americans vs. 5.1% in Caucasians (mHR: 1.27, p = 0.039) in abiraterone era and 8.9% in African Americans vs. 5.3% in Caucasians (mHR: 1.87, p < 0.001) in ARPI era. CONCLUSION: The current data indicate more favorable YLL values exhibited by African Americans in ARPI era relative to abiraterone era, that stand from lower contributions of CSM, but stable contributions of OCM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Black or African AmericanLife ExpectancyProstatic NeoplasmsWhiteAdultAgedAged, 80 and overHumansMaleMiddle AgedNeoplasm MetastasisSEER ProgramSurvival RateUnited StatesAndrostenes

Stichwörter der Autor:innen

SEER databaseprostate cancerrace/ethnicitysurvivalyears of life lost

Substanzen

abirateroneAndrostenes

Autor:innen und Institutionen

  • Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada. quarta.leonardo@hsr.it.
  • Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. quarta.leonardo@hsr.it.
  • Vita-Salute San Raffaele University, Milan, Italy. quarta.leonardo@hsr.it.
  • Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Division of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy.
  • Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

ORCID-Profile: Leonardo Quarta

Zitieren

APA

Quarta, L., Nicolazzini, M., Catanzaro, C., Polverino, F., Petix, M., Filzmayer, M., Lee, N. J., Goyal, J. A., Volpe, A., Schiavina, R., Longo, N., Carmignani, L., Chun, F. K. H., Shariat, S. F., Barletta, F., Stabile, A., Gandaglia, G., Montorsi, F., Saad, F., …, & Karakiewicz, P. I. (2026). Years of life lost and mortality rates from metastatic prostate cancer in contemporary African Americans vs. Caucasians. World Journal of Urology, 44(1). https://doi.org/10.1007/s00345-026-06295-3

Vancouver

Quarta L, Nicolazzini M, Catanzaro C, Polverino F, Petix M, Filzmayer M, et al. Years of life lost and mortality rates from metastatic prostate cancer in contemporary African Americans vs. Caucasians. World Journal of Urology. 2026;44(1). doi:10.1007/s00345-026-06295-3

BibTeX
@article{Quarta2026,
  author = {Quarta, Leonardo and Nicolazzini, Michele and Catanzaro, Calogero and Polverino, Federico and Petix, Michele and Filzmayer, Maximilian and Lee, Nick J and Goyal, Jordan A and Volpe, Alessandro and Schiavina, Riccardo and Longo, Nicola and Carmignani, Luca and Chun, Felix K H and Shariat, Shahrokh F and Barletta, Francesco and Stabile, Armando and Gandaglia, Giorgio and Montorsi, Francesco and Saad, Fred and Briganti, Alberto and Karakiewicz, Pierre I},
  title = {Years of life lost and mortality rates from metastatic prostate cancer in contemporary African Americans vs. Caucasians},
  journal = {World Journal of Urology},
  year = {2026},
  volume = {44},
  number = {1},
  doi = {10.1007/s00345-026-06295-3}
}
Kostenlos starten →